No Data
No Data
Top Premarket Gainers
Express News | BioVie Inc - on Track to Receive Additional $12.6 Mln in Grant Funding From U.S. Department of Defense ("Dod") and Initiate Its Phase 2 Trial
Express News | BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long Covid
BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID
BioVie Announces Data From Oral Bezisterim Presentation At Aging Research And Drug Discovery Meeting, Says 'Bezisterim Appears to Possess Broad Homeostatic Properties Relevant to Inflammation and Human Disorders Related to Aging'
Express News | BioVie Inc -Patients Treated With Bezisterim Experienced 2 to 4 Years Age Deceleration Advantage Compared to Placebo